CN106261817A - A kind of efficient enzymolysis Application way of Sanguis sus domestica - Google Patents
A kind of efficient enzymolysis Application way of Sanguis sus domestica Download PDFInfo
- Publication number
- CN106261817A CN106261817A CN201610658269.8A CN201610658269A CN106261817A CN 106261817 A CN106261817 A CN 106261817A CN 201610658269 A CN201610658269 A CN 201610658269A CN 106261817 A CN106261817 A CN 106261817A
- Authority
- CN
- China
- Prior art keywords
- enzymolysis
- sus domestica
- sanguis sus
- blood cell
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000282894 Sus scrofa domesticus Species 0.000 title claims abstract description 53
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 88
- 229910052742 iron Inorganic materials 0.000 claims abstract description 53
- 239000000047 product Substances 0.000 claims abstract description 44
- 210000002381 plasma Anatomy 0.000 claims abstract description 43
- 210000000601 blood cell Anatomy 0.000 claims abstract description 40
- 239000000843 powder Substances 0.000 claims abstract description 33
- 239000006228 supernatant Substances 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 238000001556 precipitation Methods 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000013522 chelant Substances 0.000 claims abstract description 10
- 102000004190 Enzymes Human genes 0.000 claims abstract description 8
- 108090000790 Enzymes Proteins 0.000 claims abstract description 8
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 4
- 239000002244 precipitate Substances 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 62
- 230000004044 response Effects 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 6
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 108091005508 Acid proteases Proteins 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 235000019419 proteases Nutrition 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 108090000145 Bacillolysin Proteins 0.000 claims description 2
- 108091005658 Basic proteases Proteins 0.000 claims description 2
- 108010004032 Bromelains Proteins 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 102000035092 Neutral proteases Human genes 0.000 claims description 2
- 108091005507 Neutral proteases Proteins 0.000 claims description 2
- 108090000526 Papain Proteins 0.000 claims description 2
- 235000019835 bromelain Nutrition 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 241000040710 Chela Species 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000019834 papain Nutrition 0.000 claims 1
- 229940055729 papain Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 20
- 229910052799 carbon Inorganic materials 0.000 abstract description 13
- 230000008569 process Effects 0.000 abstract description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 10
- 238000012545 processing Methods 0.000 abstract description 10
- 238000002156 mixing Methods 0.000 abstract description 6
- 101000993059 Homo sapiens Hereditary hemochromatosis protein Proteins 0.000 abstract description 4
- 230000006866 deterioration Effects 0.000 abstract description 4
- 239000013067 intermediate product Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- -1 organic acid iron salt Chemical class 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- NJFMNPFATSYWHB-UHFFFAOYSA-N ac1l9hgr Chemical compound [Fe].[Fe] NJFMNPFATSYWHB-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VXHQISAVDZRPQZ-MUWMCQJSSA-M C[C@H]([C@@H](C([O-])=O)N)O.[Fe+2] Chemical compound C[C@H]([C@@H](C([O-])=O)N)O.[Fe+2] VXHQISAVDZRPQZ-MUWMCQJSSA-M 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004277 Ferrous carbonate Substances 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010044278 Trace element deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229960004652 ferrous carbonate Drugs 0.000 description 1
- 235000019268 ferrous carbonate Nutrition 0.000 description 1
- RAQDACVRFCEPDA-UHFFFAOYSA-L ferrous carbonate Chemical compound [Fe+2].[O-]C([O-])=O RAQDACVRFCEPDA-UHFFFAOYSA-L 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 229960001604 ferrous succinate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 229910000015 iron(II) carbonate Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- APVZWAOKZPNDNR-UHFFFAOYSA-L iron(ii) citrate Chemical compound [Fe+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O APVZWAOKZPNDNR-UHFFFAOYSA-L 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The efficient enzymolysis Application way of a kind of Sanguis sus domestica, with Sanguis sus domestica as raw material, comprises the following steps: (1), by Sanguis sus domestica anticoagulant, is centrifuged and generates blood plasma liquid and blood cell liquid, be separately dried prepared plasma powder and blood cell powder；(2) plasma powder and blood cell powder are carried out respectively enzymolysis, generate blood plasma enzymolysis solution and blood cell enzymolysis solution, enzyme denaturing；(3) blood plasma enzymolysis solution and blood cell enzymolysis solution are centrifuged, respectively obtain cleer and peaceful precipitation on blood plasma enzymolysis solution, cleer and peaceful precipitation on blood cell enzymolysis solution；(4) blood cell, blood plasma enzymolysis liquid precipitate acidolysis are become ionic state；(5) by blood plasma enzymolysis solution supernatant, blood cell enzymolysis solution supernatant and the mixing of step (4) gained acidolysis solution, chelate and i.e. obtain Sanguis sus domestica source supplements-iron product.The present invention can efficiently make full use of Sanguis sus domestica enzymolysis processing intermediate product, prepares high Fe contained supplements-iron and multiple addition product, and raw material availability is high, and physical deterioration is extremely low, and the utilization rate of carbon is the highest, significantly reduces comprehensive process cost.
Description
Technical field
The invention belongs to Sanguis sus domestica processing, utilize technical field, be specifically related to the Sanguis sus domestica enzymolysis processing profit of a kind of high usage
With method and products obtained therefrom.
Background technology
Sanguis sus domestica is a kind of side-product after pig is slaughtered, containing rich in protein, vitamin and mineral.It contains 18 kinds
Aminoacid, including 8 kinds of essential amino acids, additionally Sanguis sus domestica iron content is the abundantest, and according to surveying and determination, every 100g whole blood levels of iron content is up to
45mg, in porcine blood plasma, iron content is up to 6.4%, additionally, many possibly together with calcium, phosphorus, potassium, sodium, magnesium, zinc, copper, manganese, selenium etc. in Sanguis sus domestica
Plant trace element.At present, China more developed country in terms of Sanguis sus domestica exploitation falls behind, except part makees edible and processing blood powder
Outward, major part is not fully developed utilization.Therefore, comprehensive development and utilization Sanguis sus domestica resource, before having the most wide market
Scape.
Iron deficiency anemia refers to that internal storage ferrum is not enough, affects a kind of minicell caused by hemoglobin synthesis, low color
Disposition anemia, is modal one in anemia all over the world, is also one of important global Deficiency disease.Iron-deficient is lean
The preventing and treating of blood mainly realizes by taking iron supplementary.Occur in that in the market miscellaneous for human calcium, ferrum, copper,
The functional supplement of the trace element deficiency exploitations such as zinc, especially iron-supplementing preparation: first on behalf of inorganic salts trace elements iron
Additive, conventional has ferrous sulfate, ferrous chloride and ferrous carbonate etc., although these inorganic iron iron supplementary iron contents are high, but
It is easily to cause food discoloration with the combination such as sulfide, polyphenol, go bad, lipid oxidation, there is metal rust taste, and gastrointestinal is had seriously
Zest, long-term taking can cause nausea,vomiting,diarrhea, is difficult to fully be digested and assimilated by human body；Second on behalf of simply having
Machine Barbiturates, absorbance and the bioavailability of its ferrum increase, such as ferrous citrate, ferrous fumarate etc., i.e. solubility
Small molecular organic acid iron salt, this kind of Organic Iron iron supplementary utilizes gastric acid to make iron ion slowly release after being taken by patient, keeps away
Having exempted from medicine moment concentration under one's belt excessive, stimulation greatly reduces, but ferrous salt character is unstable, produces and store tired
Difficulty, is easily generated abnormal flavour；Above-mentioned two generation iron supplementary are all to be absorbed by the body by ion channel absorption features, free iron ion meeting
Cause some vitamin to inactivate, the most also can cause radical reaction, cause cell senescence and death；The third generation is amino acids
Iron supplementary, such as glycine ferrous, ferrous methionine and iron (II)-threonine etc., is presently commercially available topmost iron supplementary, and it overcomes
The defect of front two generation iron supplementary, has that anti-interference is good, stability is strong and the advantage such as easy absorption, but it also exists product list
One, the shortcoming that specificity is too strong and price is high；Forth generation iron supplementary is more preferable with stability, bioavailability is higher, with low cost
For final goal, such as heme iron, polyferose and polypeptide ferrum etc., research shows, polypeptide chelate iron is a kind of new bio state ferrum,
Can directly be absorbed by intestinal mucosa cells, not producing digestive tract stimulates, and bioavailability is high, is preferable iron supplementary, therefore, opens
Send out polypeptide chelate iron to become forth generation iron supplementary and become of today and pay close attention to and study hotspot.
At present, with Sanguis sus domestica as raw material substrate, the preparation technology relevant to polypeptide chelate ferrum mainly has: (1) utilizes enzymatic isolation method
Extract polypeptide chelate ferrum, make the finished products such as aminoacids complex, peptide ferrum wet product, blood bovine, as Chinese patent CN101480254A,
CN101337964A and CN105274159A；(2) be prepared as spray-dried plasma protein, blood globulin powder or fibrin powder utilizes shape
Formula, such as Chinese patent CN104256045A, CN102125164A, CN104664040A.But above-mentioned existing preparation technology existence
Matter loss is very serious, and utilization rate is relatively low, the shortcoming that product structure is single, and finished product iron content is still needed raising.
Summary of the invention
The drawbacks described above existed for existing Sanguis sus domestica processing and utilization technique and product, the present invention provides the efficient of a kind of Sanguis sus domestica
Enzymolysis Application way, the method can the most efficiently utilize Sanguis sus domestica enzymolysis processing intermediate product, prepares high Fe contained ferrum and mends
Filling agent and multiple addition product, raw material availability is high, and physical deterioration is extremely low, and the utilization rate of carbon is the highest, significantly reduces comprehensive
Close processing cost.
For realizing object above, the present invention by the following technical solutions:
The efficient enzymolysis Application way of a kind of Sanguis sus domestica, with fresh Sanguis sus domestica as raw material, comprises the following steps:
(1) Sanguis sus domestica is added sodium citrate anticoagulant, in 3000～6000r/min centrifugal generation blood plasma liquid and blood cell liquid, point
Gan Zao not prepare plasma powder and blood cell powder；
(2) step (1) gained plasma powder and blood cell powder are carried out enzymolysis, enzyme addition 0.1～2.0wt%, substrate respectively
Concentration 2～10wt%, enzymolysis pH 3～9, hydrolysis temperature 40～60 DEG C, enzymolysis time 1～10h, generate blood plasma enzymolysis solution respectively
With blood cell enzymolysis solution, in 80～100 DEG C of water-bath enzyme denaturing 3～10min, standby；
(3) step (2) gained blood plasma enzymolysis solution and blood cell enzymolysis solution are centrifuged respectively at 3000～5500r/min, respectively
Obtain on blood plasma enzymolysis solution cleer and peaceful precipitation in cleer and peaceful precipitation, and blood cell enzymolysis solution, standby；
(4) step (3) gained blood plasma, the precipitation acidolysis of blood cell enzymolysis solution are become ionic state, standby；
(5) by step (3) gained blood plasma enzymolysis solution supernatant, step (3) gained blood cell enzymolysis solution supernatant and step (4) institute
Obtain the mixing of acidolysis solution, in 5～55 DEG C, chelate under the conditions of pH3～9, in the response time 1～5h, be dried to powder, obtain Sanguis sus domestica
Source supplements-iron product, the loss rate of carbon in detection product preparation flow.
Further, the method also comprises the steps: step (2) gained blood plasma enzymolysis solution, step (3) gained blood cell
Enzymolysis solution supernatant and the mixing of step (4) gained acidolysis solution, in 5～55 DEG C, chelate under the conditions of pH3～9, the response time
1～5h, it is dried to powder, obtains Sanguis sus domestica source supplements-iron addition product.
Further, the method also comprises the steps: step (3) gained blood plasma enzymolysis solution supernatant and step (4)
Gained acidolysis solution mixes, and in 5～55 DEG C, chelates under the conditions of pH3～9, in the response time 1～5h, is dried to powder, obtains pig
Blood source supplements-iron addition product.
Further, the method also comprises the steps: to take step (2) gained blood plasma enzymolysis solution and the acid of step (4) gained
Solution liquid mixes, in 5～55 DEG C, chelate under conditions of pH 3～9, in the response time 1～5h, be dried to powder, obtain Sanguis sus domestica source
Supplements-iron addition product.
Further, the method also comprises the steps: to take step (3) gained blood cell enzymolysis solution supernatant and step (4) institute
Obtain acid hydrolysis solution mixing, chelate under conditions of 5～55 DEG C, pH3～9, in the response time 1～5h, be dried to powder, obtain Sanguis sus domestica
Source supplements-iron addition product.
Preferably, step (2) described enzymolysis uses alkaline protease, acid protease, neutral protease, Papain
Enzyme, bromelain, flavor protease and animal protease one or more of which are compounding.
Preferably, the dilution heat of sulfuric acid of dilute hydrochloric acid solution, 1～the 9mol/L of step (4) described acidolysis employing 1～5mol/L
Or 36～the acetum of 38%.
Preferably, described drying mode is selected from lyophilization, is vacuum dried or is spray-dried.
Compared with existing Sanguis sus domestica process and utilization technology, the present invention has the advantage that
With Sanguis sus domestica as raw material, make full use of its enzymolysis processing intermediate product blood plasma enzymolysis solution, blood cell enzymolysis solution, blood
Ball, blood plasma enzymolysis solution supernatant and precipitation, precipitation acidolysis solution etc., coordinate simultaneously and use specific enzymolysis, separate, the technique bar such as be dried
Part and parameter, can prepare high Fe contained supplements-iron and the multiple supplements-iron addition product of different iron-holder, pole
The earth improves Sanguis sus domestica raw material availability, and whole process physical deterioration is the lowest, and the utilization rate of carbon is the highest, significantly reduces comprehensive
Close processing cost, the kind of simultaneously abundant and perfect supplements-iron product and form, can select the most flexibly
Select, proportioning and combination, significantly improve added value of product, be a kind of Sanguis sus domestica highly-efficient processing Application way, energy-conserving and environment-protective, have good
Good economic benefit and wide market application foreground.
Accompanying drawing explanation
Fig. 1 is the process chart of Sanguis sus domestica enzymolysis Application way of the present invention.
Detailed description of the invention
Below in conjunction with the accompanying drawings, by embodiment, the detailed description of the invention of the present invention is described further.
Preparation embodiment
Embodiment 1
(1) fresh Sanguis sus domestica 1kg is added the sodium citrate anticoagulant of 2.5wt%, centrifugal 5500r/min, generate blood cell liquid and
Blood plasma liquid, lyophilizing obtains 150g plasma powder and 40g blood cell powder；
(2) blood cell powder and plasma powder are carried out enzymolysis (acid protease, original ph 4, concentration of substrate 7wt%, enzyme respectively
Addition 0.2wt%, enzymolysis time 5h, hydrolysis temperature 48 DEG C), generating blood plasma enzymolysis solution and blood cell enzymolysis solution, 100 DEG C of water-baths are gone out
Enzyme 10min, standby；
(3) blood cell enzymolysis solution is centrifugal (4500r/min), obtains upper cleer and peaceful precipitation, and blood plasma enzymolysis solution is centrifuged (4500r/
Min), cleer and peaceful precipitation is obtained；
(4) 5mol/L dilution heat of sulfuric acid (dilution heat of sulfuric acid and precipitation volume are used in step (3) gained is deposited in centrifuge tube
Ratio 1: 1) acidolysis, generate ionic state ferrum；
(5) by step (3) gained blood plasma enzymolysis solution supernatant, blood cell enzymolysis solution supernatant and step (4) gained acidolysis solution
Mixing, regulates pH to 7.0, carries out chelatropic reaction 2.5h in 25 DEG C, be lyophilized into powder, obtain Sanguis sus domestica source supplements-iron finished product 1, detection
Going out whole flow process carbon loss rate is 9.43%.
Embodiment 2
On the basis of embodiment 1, by step (2) gained blood plasma enzymolysis solution 1000ml, step (3) gained blood cell enzymolysis solution
Supernatant 500ml mixes with step (4) gained acidolysis solution 350ml, regulates pH to 7.5, carries out chelatropic reaction 2h, lyophilizing in 25 DEG C
Cheng Fen, obtains Sanguis sus domestica source supplements-iron addition product 1, detects that whole flow process carbon loss rate is 8.64%.
Embodiment 3
On the basis of embodiment 1, by molten to step (3) gained blood plasma enzymolysis solution supernatant 500ml and step (4) gained acidolysis
Liquid 350ml mixes, and regulates pH to 6.8, carries out chelatropic reaction 3h in 25 DEG C, be lyophilized into powder, obtains Sanguis sus domestica source supplements-iron and adds
Product 2, detects that whole flow process carbon loss rate is 8.51%.
Embodiment 4
On the basis of step described in embodiment 1, take step (2) gained blood plasma enzymolysis solution 1000ml and the acid of step (4) gained
Solve liquid 350ml mixing, in pH 6.5, carry out chelatropic reaction 3h under the conditions of 40 DEG C, be lyophilized into powder, obtain Sanguis sus domestica source supplements-iron attached
Add product 3, detect that whole flow process carbon loss rate is 8.22%.
Embodiment 5
On the basis of step described in embodiment 1, take step (3) gained blood cell enzymolysis solution supernatant 500ml and step (4) gained
Acid hydrolysis solution 350ml mixes, and in pH 7.5, carries out chelatropic reaction 2h, be lyophilized into powder under the conditions of 39 DEG C, obtain Sanguis sus domestica source supplements-iron
Addition product 4, detects that whole flow process carbon loss rate is 8.14%.
Using plasma aes determination iron content, concrete measurement result is as shown in the table:
Table 1 iron content measurement result
| Kind | Iron content (mg/100g) |
| Blood cell enzymolysis solution supernatant (step 3) | 920 |
| Blood cell enzymolysis solution precipitation (step 3) | 2200 |
| Supplements-iron finished product 1 | 2811 |
| Supplements-iron addition product 1 | 2612 |
| Supplements-iron addition product 2 | 2506 |
| Supplements-iron addition product 3 | 2455 |
| Supplements-iron addition product 4 | 2697 |
As seen from the above table, intermediate products (blood cell enzymolysis solution) and the finished product of present invention process is respectively provided with the highest ferrum and contains
Amount, and the supplements-iron addition product of different iron content can be prepared, raw material availability is high.In embodiment 1～embodiment 5
In, the carbonizable substance change in preparation process of supplements-iron finished product and addition product thereof is the least, and all loss is less than 10%.City
Selling iron supplementary ferrous succinate sheet (turn of speed luxuriant and rich with fragrance) iron-holder is 2000mg/100g, less than supplements-iron finished product in the present invention and attached
Add the iron-holder of product.
From above-described embodiment, preparation technology of the present invention significantly improves the utilization rate of Sanguis sus domestica raw material, and physical deterioration is non-
The lowest, the utilization rate of carbon is the highest, can prepare high Fe contained Sanguis sus domestica source supplements-iron and multiple addition product, improve product
Added value, advantageously reduces comprehensive process cost.
If no special instructions, involved by embodiment 1～embodiment 5, experimental facilities, instrument and raw material are commercially available general product
Product.
It is understood that above with respect to the specific descriptions of the present invention, be merely to illustrate the present invention and be not limited to this
Technical scheme described by inventive embodiments.It will be understood by those within the art that, still the present invention can be carried out
Amendment or equivalent, to reach identical technique effect；As long as meet use needs, all protection scope of the present invention it
In.
Claims (8)
1. an efficient enzymolysis Application way for Sanguis sus domestica, with fresh Sanguis sus domestica as raw material, it is characterised in that comprise the following steps:
(1) Sanguis sus domestica is added sodium citrate anticoagulant, in 3000～6000r/min centrifugal generation blood plasma liquid and blood cell liquid, do respectively
Dry prepared plasma powder and blood cell powder；
(2) step (1) gained plasma powder and blood cell powder are carried out enzymolysis, enzyme addition 0.1～2.0wt%, concentration of substrate 2 respectively
～10wt%, enzymolysis pH3～9, hydrolysis temperature 40～60 DEG C, enzymolysis time 2～10h, generate blood plasma enzymolysis solution and blood cell respectively
Enzymolysis solution, in 80～100 DEG C of water-bath enzyme denaturing 3～10min, standby；
(3) step (2) gained blood plasma enzymolysis solution and blood cell enzymolysis solution are centrifuged respectively at 3000～5500r/min, respectively obtain
On blood plasma enzymolysis solution, cleer and peaceful precipitation in cleer and peaceful precipitation, and blood cell enzymolysis solution, standby；
(4) step (3) gained blood cell, blood plasma enzymolysis liquid precipitate acidolysis are become ionic state, standby；
(5) by step (3) gained blood plasma enzymolysis solution supernatant, step (3) gained blood cell enzymolysis solution supernatant and the acid of step (4) gained
Solution solution mixes, and in 5～55 DEG C, chelates under the conditions of pH5～8, in the response time 1～5h, is dried to powder, obtains Sanguis sus domestica source ferrum
Supplement product.
The efficient enzymolysis Application way of Sanguis sus domestica the most according to claim 1, it is characterised in that also comprise the steps: step
Suddenly (2) gained blood plasma enzymolysis solution, step (3) gained blood cell enzymolysis solution supernatant mixes with step (4) gained acidolysis solution, in 5～
55 DEG C, chelate under the conditions of pH5～8, in the response time 1～5h, be dried to powder, obtain Sanguis sus domestica source supplements-iron addition product.
The efficient enzymolysis Application way of Sanguis sus domestica the most according to claim 1, it is characterised in that also comprise the steps: step
Suddenly (3) gained blood plasma enzymolysis solution supernatant mixes with step (4) gained acid hydrolysis solution, in 5～55 DEG C, carries out chela under conditions of pH5～8
Close, in the response time 1～5h, be dried to powder, obtain Sanguis sus domestica source supplements-iron addition product.
The efficient enzymolysis Application way of Sanguis sus domestica the most according to claim 1, it is characterised in that also comprise the steps: to take step
Suddenly (2) gained blood plasma enzymolysis solution mixes with step (4) gained acid hydrolysis solution, in 5～55 DEG C, chelates under conditions of pH5～8,
In the response time 1～5h, it is dried to powder, obtains Sanguis sus domestica source supplements-iron addition product.
The efficient enzymolysis Application way of Sanguis sus domestica the most according to claim 1, it is characterised in that also comprise the steps: to take step
Suddenly (3) gained blood cell enzymolysis solution supernatant mixes with step (4) gained acid hydrolysis solution, in 5～55 DEG C, carries out chela under conditions of pH5～8
Close, in the response time 1～5h, be dried to powder, obtain Sanguis sus domestica source supplements-iron addition product.
The efficient enzymolysis Application way of Sanguis sus domestica the most according to claim 1, it is characterised in that: step (2) described enzymolysis is adopted
With alkaline protease, acid protease, neutral protease, papain, bromelain, flavor protease and animal proteinum
Enzyme one or more of which compounds.
The efficient enzymolysis Application way of Sanguis sus domestica the most according to claim 1, it is characterised in that: step (4) described acidolysis is adopted
With 1～5mol/L dilute hydrochloric acid solution, 1～9mol/L dilution heat of sulfuric acid or 36～the acetum of 38%.
8. according to the efficient enzymolysis Application way of the Sanguis sus domestica described in any one of Claims 1 to 5, it is characterised in that: described dry
Mode is selected from lyophilization, is vacuum dried or is spray-dried.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610658269.8A CN106261817A (en) | 2016-08-11 | 2016-08-11 | A kind of efficient enzymolysis Application way of Sanguis sus domestica |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610658269.8A CN106261817A (en) | 2016-08-11 | 2016-08-11 | A kind of efficient enzymolysis Application way of Sanguis sus domestica |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106261817A true CN106261817A (en) | 2017-01-04 |
Family
ID=57668796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610658269.8A Pending CN106261817A (en) | 2016-08-11 | 2016-08-11 | A kind of efficient enzymolysis Application way of Sanguis sus domestica |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106261817A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114672413A (en) * | 2021-05-20 | 2022-06-28 | 申昌南 | System for producing amino acid using plasma and blood cells separated from whole blood |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300732A (en) * | 2000-12-28 | 2001-06-27 | 内蒙古草原兴发股份有限公司 | Process for extracting heme from animal blood |
| CN101353686A (en) * | 2008-09-09 | 2009-01-28 | 浙江大学 | Production method of haemachrome and decolorizing blood plasma albumen powder |
| CN101664543A (en) * | 2009-09-02 | 2010-03-10 | 张滨 | Hemokinin-iron oral liquid |
| CN101979532A (en) * | 2010-10-13 | 2011-02-23 | 江苏省江大绿康生物工程技术研究有限公司 | Method for comprehensively using pig blood |
| CN102942628A (en) * | 2012-08-20 | 2013-02-27 | 淮北恩彼饲料有限公司 | Co-production method for extracting bioactive substances from pig blood |
| CN104431413A (en) * | 2014-10-16 | 2015-03-25 | 浙江索纳克生物科技有限公司 | Method of comprehensively utilizing pig blood |
| CN105349603A (en) * | 2015-11-19 | 2016-02-24 | 桐城市雨润生物科技有限公司 | Method for producing protein peptide and hemachrome through enzymatic hydrolysis of pig blood |
| CN105506044A (en) * | 2015-12-28 | 2016-04-20 | 桐城市雨润生物科技有限公司 | Preparation method for blood cell protein peptide chelated calcium microcapsule preparation |
-
2016
- 2016-08-11 CN CN201610658269.8A patent/CN106261817A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300732A (en) * | 2000-12-28 | 2001-06-27 | 内蒙古草原兴发股份有限公司 | Process for extracting heme from animal blood |
| CN101353686A (en) * | 2008-09-09 | 2009-01-28 | 浙江大学 | Production method of haemachrome and decolorizing blood plasma albumen powder |
| CN101664543A (en) * | 2009-09-02 | 2010-03-10 | 张滨 | Hemokinin-iron oral liquid |
| CN101979532A (en) * | 2010-10-13 | 2011-02-23 | 江苏省江大绿康生物工程技术研究有限公司 | Method for comprehensively using pig blood |
| CN102942628A (en) * | 2012-08-20 | 2013-02-27 | 淮北恩彼饲料有限公司 | Co-production method for extracting bioactive substances from pig blood |
| CN104431413A (en) * | 2014-10-16 | 2015-03-25 | 浙江索纳克生物科技有限公司 | Method of comprehensively utilizing pig blood |
| CN105349603A (en) * | 2015-11-19 | 2016-02-24 | 桐城市雨润生物科技有限公司 | Method for producing protein peptide and hemachrome through enzymatic hydrolysis of pig blood |
| CN105506044A (en) * | 2015-12-28 | 2016-04-20 | 桐城市雨润生物科技有限公司 | Preparation method for blood cell protein peptide chelated calcium microcapsule preparation |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114672413A (en) * | 2021-05-20 | 2022-06-28 | 申昌南 | System for producing amino acid using plasma and blood cells separated from whole blood |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102286105B (en) | Sesame protein source metal chelating peptide and peptide trace element chelate and application thereof | |
| US4172072A (en) | Buffered enzymatically produced metal proteinates | |
| CN106538845A (en) | A kind of chelating ferrous preparation method of marine protein peptide | |
| CN102392010B (en) | Protease extracted by using squid viscera as raw materials and extraction method and application thereof | |
| CN101509030A (en) | Hydrolyzation of pig blood with complex enzyme method for producing blood peptide native | |
| CN105724784A (en) | Polypeptide zinc chelate prepared with soy protein isolate as base and preparation method | |
| CN102077901B (en) | Swine hemoglobin enzymolysis and decoloration method | |
| CN105746907A (en) | Polypeptide iron chelate prepared from soy isolate protein serving as substrate and preparation method | |
| CN105506044A (en) | Preparation method for blood cell protein peptide chelated calcium microcapsule preparation | |
| CN105624250A (en) | Enzymolysis-fermentation coupled aquatic protein active peptide preparation method | |
| CN101461440A (en) | Technique for extracting fish protein ferritin peptide from low value sea water fish and leftover protein | |
| CN105661049A (en) | Polypeptide copper chelate prepared by using soybean protein isolate as substrate and preparation method | |
| CN102860512B (en) | Preparation method of black-bone chicken peptide and iron chelated biological iron supplement | |
| CN105852134A (en) | Preparation method and application of marine polypeptide-zinc chelate | |
| RO129051A0 (en) | Process for preparing amino acid chelates with essential micro elements | |
| CN103130915A (en) | Chondroitin sulfate preparation method based on fish head cartilage | |
| CN106107574A (en) | A kind of preparation method of Sanguis sus domestica source compound microelement supplement | |
| CN105768111A (en) | Preparing method and application of ocean polypeptide-calcium chelate | |
| CN107893097A (en) | A kind of cod row protein peptides ferrous chelate compound and preparation method thereof | |
| CN106261816A (en) | A kind of Sanguis sus domestica source iron supplementary intermediate and the preparation method of finished product thereof | |
| CN106261817A (en) | A kind of efficient enzymolysis Application way of Sanguis sus domestica | |
| CN110558419A (en) | Vegetable protein peptide powder and preparation method thereof | |
| CN101589823B (en) | Production process of sea cucumber health milk | |
| CN106072662A (en) | A kind of preparation method of Corbicula fluminea polypeptide chelate zinc | |
| CN112825959A (en) | Method for extracting protein from soybeans based on eutectic solvent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |